Review Article| Volume 39, ISSUE 1, P61-72, March 2019

Download started.


Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation

  • Courtney M. Rowan
    Corresponding author.
    Department of Pediatrics, Division of Critical Care, Indiana University School of Medicine, 705 Riley Hospital Drive, Room 4900, Indianapolis, IN 46202, USA
    Search for articles by this author
  • Sophie Paczesny
    Department of Pediatrics, Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, 1044 West Walnut Street, Room R4-425, Indianapolis, IN 46202, USA

    Department of Microbiology Immunology, Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, 1044 West Walnut Street, Room R4-425, Indianapolis, IN 46202, USA
    Search for articles by this author
Published:December 17, 2018DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zeiser R.
        • Blazar B.R.
        Acute graft-versus-host disease - biologic process, prevention, and therapy.
        N Engl J Med. 2017; 377: 2167-2179
        • Paczesny S.
        • Hakim F.T.
        • Pidala J.
        • et al.
        National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: III. The 2014 Biomarker Working Group report.
        Biol Blood Marrow Transplant. 2015; 21: 780-792
        • Flomenberg N.
        • Baxter-Lowe L.A.
        • Confer D.
        • et al.
        Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.
        Blood. 2004; 104: 1923-1930
        • Martin P.J.
        • Levine D.M.
        • Storer B.E.
        • et al.
        Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.
        Blood. 2017; 129: 791-798
        • Karaesmen E.
        • Rizvi A.A.
        • Preus L.M.
        • et al.
        Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
        Blood. 2017; 130: 1585-1596
        • Tkachev V.
        • Furlan S.N.
        • Watkins B.
        • et al.
        Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.
        Sci Transl Med. 2017; 9 ([pii:eaan3085])
        • Kennedy G.A.
        • Varelias A.
        • Vuckovic S.
        • et al.
        Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
        Lancet Oncol. 2014; 15: 1451-1459
        • McDonald G.B.
        • Tabellini L.
        • Storer B.E.
        • et al.
        Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.
        Blood. 2015; 126: 113-120
        • Paczesny S.
        • Krijanovski O.I.
        • Braun T.M.
        • et al.
        A biomarker panel for acute graft-versus-host disease.
        Blood. 2009; 113: 273-278
        • Alousi A.M.
        • Weisdorf D.J.
        • Logan B.R.
        • et al.
        Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
        Blood. 2009; 114: 511-517
        • Ponce D.M.
        • Hilden P.
        • Mumaw C.
        • et al.
        High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
        Blood. 2015; 125: 199-205
        • Kanakry C.G.
        • Bakoyannis G.
        • Perkins S.M.
        • et al.
        Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.
        Haematologica. 2017; 102: 932-940
        • Nelson Jr., R.P.
        • Khawaja M.R.
        • Perkins S.M.
        • et al.
        Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.
        Biol Blood Marrow Transplant. 2014; 20: 1861-1864
        • Vander Lugt M.T.
        • Braun T.M.
        • Hanash S.
        • et al.
        ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
        N Engl J Med. 2013; 369: 529-539
        • Abu Zaid M.
        • Wu J.
        • Wu C.
        • et al.
        Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
        Blood. 2017; 129: 162-170
        • Major-Monfried H.
        • Renteria A.S.
        • Pawarode A.
        • et al.
        MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
        Blood. 2018; 131: 2846-2855
        • McDonald G.B.
        • Tabellini L.
        • Storer B.E.
        • et al.
        Predictive value of clinical findings and plasma biomarkers after fourteen days of prednisone treatment for acute graft-versus-host disease.
        Biol Blood Marrow Transplant. 2017; 23: 1257-1263
        • Hartwell M.J.
        • Ozbek U.
        • Holler E.
        • et al.
        An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
        JCI Insight. 2017; 2: e89798
        • Zhang J.
        • Ramadan A.M.
        • Griesenauer B.
        • et al.
        ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.
        Sci Transl Med. 2015; 7: 308ra160
        • Chaidos A.
        • Patterson S.
        • Szydlo R.
        • et al.
        Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
        Blood. 2012; 119: 5030-5036
        • Magenau J.M.
        • Qin X.
        • Tawara I.
        • et al.
        Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.
        Biol Blood Marrow Transplant. 2010; 16: 907-914
        • Li W.
        • Liu L.
        • Gomez A.
        • et al.
        Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.
        JCI insight. 2016; 1 ([pii:e86660])
        • Chen Y.B.
        • McDonough S.
        • Hasserjian R.
        • et al.
        Expression of CD30 in patients with acute graft-versus-host disease.
        Blood. 2012; 120: 691-696
        • Chen Y.B.
        • Perales M.A.
        • Li S.
        • et al.
        Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.
        Blood. 2017; 129: 3256-3261
        • Paczesny S.
        • Braun T.M.
        • Levine J.E.
        • et al.
        Elafin is a biomarker of graft-versus-host disease of the skin.
        Sci Transl Med. 2010; 2: 13ra12
        • Hansen J.A.
        • Hanash S.M.
        • Tabellini L.
        • et al.
        A novel soluble form of Tim-3 associated with severe graft-versus-host disease.
        Biol Blood Marrow Transplant. 2013; 19: 1323-1330
        • Harris A.C.
        • Ferrara J.L.
        • Braun T.M.
        • et al.
        Plasma biomarkers of lower gastrointestinal and liver acute GVHD.
        Blood. 2012; 119: 2960-2963
        • Ferrara J.L.
        • Harris A.C.
        • Greenson J.K.
        • et al.
        Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
        Blood. 2011; 118: 6702-6708
        • Holtan S.G.
        • DeFor T.E.
        • Panoskaltsis-Mortari A.
        • et al.
        Amphiregulin modifies the Minnesota acute graft-versus-host disease risk score: results from BMT CTN 0302/0802.
        Blood Adv. 2018; 2: 1882-1888
        • Coppell J.A.
        • Richardson P.G.
        • Soiffer R.
        • et al.
        Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
        Biol Blood Marrow Transplant. 2010; 16: 157-168
        • Lee J.H.
        • Lee K.H.
        • Kim S.
        • et al.
        Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
        Bone Marrow Transplant. 1998; 22: 883-888
        • Lee J.H.
        • Lee K.H.
        • Lee J.H.
        • et al.
        Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
        Br J Haematol. 2002; 118: 1087-1094
        • Cutler C.
        • Kim H.T.
        • Ayanian S.
        • et al.
        Prediction of veno-occlusive disease using biomarkers of endothelial injury.
        Biol Blood Marrow Transplant. 2010; 16: 1180-1185
        • Akil A.
        • Zhang Q.
        • Mumaw C.L.
        • et al.
        Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation.
        Biol Blood Marrow Transplant. 2015; 21: 1739-1745
        • Seo S.
        • Yu J.
        • Jenkins I.C.
        • et al.
        Diagnostic and prognostic plasma biomarkers for idiopathic pneumonia syndrome after hematopoietic cell transplantation.
        Biol Blood Marrow Transplant. 2018; 24: 678-686
        • Rowan C.M.
        • Gertz S.J.
        • McArthur J.
        • et al.
        Invasive mechanical ventilation and mortality in pediatric hematopoietic stem cell transplantation: a multicenter study.
        Pediatr Crit Care Med. 2016; 17: 294-302
        • Rowan C.M.
        • Moser E.A.S.
        • Bakoyannis G.
        • et al.
        Prognostic and predictive biomarkers for respiratory failure and related mortality post allogeneic hematopoietic cell transplantation.
        Biol Blood Marrow Transplant. 2018; 24: S301
        • Majhail N.S.
        • Challa T.R.
        • Mulrooney D.A.
        • et al.
        Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
        Biol Blood Marrow Transplant. 2009; 15: 1100-1107
        • Gebremedhin E.
        • Behrendt C.E.
        • Nakamura R.
        • et al.
        Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease.
        Inflammation. 2013; 36: 177-185
        • Fuji S.
        • Kim S.W.
        • Mori S.
        • et al.
        Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation.
        Transplantation. 2007; 84: 814-820
        • Johnpulle R.A.
        • Paczesny S.
        • Jung D.K.
        • et al.
        Metabolic complications precede alloreactivity and are characterized by changes in suppression of tumorigenicity 2 signaling.
        Biol Blood Marrow Transplant. 2017; 23: 529-532
      1. Teagarden AM, Moser E, Rowan CM, et al. Early ST2 levels are associated with the diagnosis of post-transplant diabetes mellitus. Paper presented at: Pediatric Academic Society 2018; Toronto, Canda.

        • Jodele S.
        • Davies S.M.
        • Lane A.
        • et al.
        Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
        Blood. 2014; 124: 645-653
        • Rosenthal J.
        Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment.
        J Blood Med. 2016; 7: 181-186
        • Rotz S.J.
        • Dandoy C.E.
        • Davies S.M.
        ST2 and endothelial injury as a link between GVHD and microangiopathy.
        N Engl J Med. 2017; 376: 1189-1190
        • Levine J.E.
        • Braun T.M.
        • Harris A.C.
        • et al.
        A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
        Lancet Haematol. 2015; 2: e21-e29
        • Bruggen M.C.
        • Petzelbauer P.
        • Greinix H.
        • et al.
        Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease.
        J Invest Dermatol. 2015; 135: 999-1006